Abacavir (ABC), a nucleoside reverse transcriptase inhibitor (NRTI), combined with lamivudine (3TC), has a better short- and long-term outcome than 3TC combined with zidovudine (ZDV) as first-line HIV therapy.\(^1,2\) In addition, children failing ABC/3TC-based first-line therapy do not select thymidine NRTI-related mutations, allowing for better choice in second-line therapy.\(^2\) With current first-line options, both first-line (stavudine (d4T)) and second-line therapy (ZDV) include a thymidine-based NRTI, thus compromising second-line regimens.\(^3-5\) In well-selected children, ABC is also an important drug in second-line and salvage therapy.\(^6\)

Of all the NRTIs, ABC is associated with the lowest rate of mitochondrial dysfunction. Types of dysfunction include lactic acidosis, peripheral neuropathy and lipoatrophy. Substitution of d4T for ABC improves mitochondrial indices and reduces adipocyte apoptosis.\(^7\) In adults, switching from d4T to ABC was superior to switching from d4T to ZDV.\(^8\) In older children, once-daily use of ABC has also been shown to be effective, thereby facilitating adherence and improving patient satisfaction, particularly when all drugs are given once daily.\(^9,10\)

Despite these advantages, ABC is rarely used as part of first-line therapy in South Africa owing to cost. Tenofovir, commonly used in adults experiencing NRTI adverse events, is not licensed for children. With large cohorts of children now on antiretroviral therapy for long periods of time, increased use of ABC is likely as NRTI adverse events become apparent. Currently, the National Department of Health permits using ABC when there have been adverse events related to other NRTIs.

Of concern is the severe and life-threatening hypersensitivity reaction (HSR) that occasionally occurs, necessitating permanent discontinuation of ABC.
avoidance of ABC in positive patients is effective in reducing HSR, and this is now the standard of care in the First World. Over-diagnosis of HSR is well documented in the absence of testing. A reduction in confirmed cases occurs when routine testing is performed.

Despite the availability of testing and the recommendation to test, there is a debate as to the cost effectiveness and cost benefit of testing in ethnic groups where HLA-B*5701 is not prevalent.

There are no data on the prevalence of HLA-B*5701 in the various South African ethnic groups. Full genetic screening for HLA-B*5701 is very costly. Cheaper methods involving PCR for small sequences of the gene are currently under review. Although full testing is available in South Africa, patients in the public sector do not have access. We recommend that testing be offered to all patients where affordable, regardless of ethnic group, until more information is available. However, it is reasonable to use ABC without prior screening if there is no alternative.

It is important to remember that HSR has been reported in patients negative for HLA-B*5701. In patients in whom HSR reaction was diagnosed and who subsequently tested negative for HLA-B*5701, ABC remains contraindicated.

CLINICAL FEATURES AND DIAGNOSIS OF ABC HSR

Diagnosis of ABC HSR is complicated by its subtle initial features. Also, other drugs such as trimethoprim-sulfamethoxazole, nevirapine and efavirenz are known to cause hypersensitivity and should be recognised. Distinguishing the ABC HSR from other drug-related adverse events, intercurrent infections and even immune reconstitution inflammatory syndrome may be particularly difficult when ABC is used as first-line therapy, as all drugs are initiated simultaneously. In addition, ABC initiation may lead to symptoms that are similar but not related to HSR, including nausea and vomiting, fever and rash. These reactions are usually mild.

Ninety-four per cent of patients who experience HSR do so within 6 weeks after initiation of therapy. The median time to onset is 11 days, but symptoms can start on the first day and have been reported up to 318 days later. ABC HSR has occurred in patients who interrupted therapy without having had hypersensitivity and subsequently restart, but this is believed to be rare. A single case of ABC HSR after switching from twice daily to once daily administration has also been reported. Vigilance for the duration of ABC exposure is required.

The ABC HSR is a multi-organ process manifesting signs or symptoms from at least two of the following groups:

- **Fever** is the most common manifestation of ABC HSR, occurring in 80% of cases. Chills have been reported to accompany fever.
- **Rash** is experienced by 70% of cases, and pruritus can also occur. In contrast to the rash caused by non-NRTIs and sulfonamides, it is often mild and may go unnoticed by patients. When rash occurs in the absence of other features of HSR, ABC should not be discontinued.
- **Gastro-intestinal symptoms** such as nausea, vomiting, diarrhea and abdominal pain are all features of HSR but may also occur in the absence of HSR, particularly when ABC is used with ZDV. Therefore, as with rash, patients with isolated gastro-intestinal symptoms should not discontinue ABC but should be followed up closely.
- **Constitutional symptoms** include fatigue, myalgias and generalised malaise.
- **Respiratory symptoms** occur in 18% of cases and include dyspnoea, cough and pharyngitis. Symptoms may be difficult to distinguish from those caused by influenza and other respiratory viruses. Respiratory symptoms together with abdominal symptoms suggest HSR rather than influenza or other respiratory illness.

Clusters and combinations of symptoms are important in the diagnosis of ABC HSR. Table 1 illustrates the frequency of some combinations.

<table>
<thead>
<tr>
<th>Systems and combinations</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 or 4 organ systems</td>
<td>49</td>
</tr>
<tr>
<td>Fever and rash</td>
<td>20</td>
</tr>
<tr>
<td>Fever and GIT</td>
<td>8</td>
</tr>
<tr>
<td>Skin and GIT</td>
<td>3</td>
</tr>
<tr>
<td>Skin and constitutional</td>
<td>3</td>
</tr>
<tr>
<td>Other combinations</td>
<td>17</td>
</tr>
</tbody>
</table>

With ABC HSR, there is an accentuation of symptoms in the hours immediately after the dose and worsening of symptoms with each subsequent dose. A number of case reports illustrate the varied clinical presentation, with Kawasaki-like illness, prominent exanthema and even disseminated intravascular coagulation being seen.

If ABC is not terminated, or if it is re-initiated after temporary cessation, the HSR will progress to hypotension, renal dysfunction, bronchospasm and ultimately death.

Abnormal laboratory findings may include leucopenia, anaemia and thrombocytopenia, as well as elevations
in transaminases, urea, creatinine and lactate dehydrogenase (LDH). Eosinophilia is usually absent. Patch testing is currently only a research tool.

Termination of therapy is followed by rapid improvement in the symptoms.

Rechallenging with ABC leads to anaphylaxis and should be avoided even in cases where there was diagnostic uncertainty.

In Table II we set out the features of the first 3 cases of suspected HSR seen at the Tygerberg Children’s Hospital Family Clinic for HIV. Of note is that HSR was documented in children across the racial spectrum. In all patients there was progression of symptoms over time and in 1 case there was a clear increase in severity associated with dosing. All children had abdominal symptoms and nonspecific rash. In these cases, children were stable on other ART drugs as they had all switched to ABC because of d4T toxicity.

### MANAGEMENT OF PATIENTS INITIATING ABC

On commencement of ABC, patients should be counselled in detail about the possible signs of HSR and be advised to contact their care provider should any occur. To avoid confusion, therapy should not be initiated in patients with intercurrent symptoms. It is advisable for patients to discuss symptoms early with the clinician rather than terminating therapy without consultation. Where termination without consultation occurs, ABC cannot be reinitiated. Patients should also be made aware of the special ‘patient alert card’ that comes in the packaging. This card should be presented to any health care provider who sees the child, especially when care is not given by the usual provider. Providers at emergency facilities may be less familiar with this condition, and where possible contact information for the usual care provider should be supplied as well.

Deciding whether to terminate therapy in a patient with suggestive symptoms can be difficult given the very nonspecific nature of the presentation. A detailed medical history should be obtained. The following should be considered:

- When was ABC initiated? In the case of ABC HSR, usually within the past 6 weeks.
- Are two or more systems involved?
- Do the symptoms increase with each dose?
- Are the symptoms exacerbated just after the dose?
- Do the symptoms fit into the well-recognised clusters?
- What other medications/medication is the patient taking, and what was the timing of their initiation related to the ABC?

If patients present with mild symptoms and it is not clear whether symptoms are due to HSR, the clinician may consider allowing an additional dose. The patient should be able to report back, or hospitalisation may be required for observation. If symptoms worsen, ABC should be terminated immediately and permanently. If symptoms do not worsen, ABC can be carefully con-

### TABLE II. CLINICAL FEATURES IN 3 CHILDREN DIAGNOSED WITH ABC HSR AT TYGERBERG CHILDREN’S HOSPITAL AFTER A SINGLE DRUG SUBSTITUTION OF STAVUDINE FOR LIPO-ATROPHY

<table>
<thead>
<tr>
<th></th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Race</strong></td>
<td>White</td>
<td>Coloured</td>
<td>Black</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>9</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td>Female</td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td><strong>Time to onset of symptoms</strong></td>
<td>&lt;1 day</td>
<td>9 days</td>
<td>2 months</td>
</tr>
<tr>
<td><strong>Accentuation with dose</strong></td>
<td>Yes</td>
<td>Uncertain</td>
<td>Uncertain</td>
</tr>
<tr>
<td><strong>Increasing severity</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Time after onset to presentation to TCH (days)</strong></td>
<td>1</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td><strong>Fever</strong></td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td><strong>Rash</strong></td>
<td>Blotchy, erythematous on neck and hands</td>
<td>Extensive maculopapular on trunk, arms and legs</td>
<td>Fine papular rash on the chest</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>Loss of appetite</td>
<td>Loose stools</td>
<td>Abdominal pain and tenderness</td>
</tr>
<tr>
<td><strong>Constitutional</strong></td>
<td>Myalgias</td>
<td>Lethargy</td>
<td>Vomiting</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td>No</td>
<td>No</td>
<td>Cough</td>
</tr>
<tr>
<td><strong>Number of systems affected</strong></td>
<td>3</td>
<td>4</td>
<td>2 - 3 days</td>
</tr>
<tr>
<td><strong>Time to resolution</strong></td>
<td>48 hours</td>
<td>5 days</td>
<td>4</td>
</tr>
<tr>
<td><strong>HLA-B*5701</strong></td>
<td>Negative – tested after the HSR</td>
<td>Positive – tested after the HSR</td>
<td>Negative – tested after the HSR</td>
</tr>
</tbody>
</table>
Clinicians treating children need to be very aware of the usefulness of ABC. Although there is no information on the prevalence of either ABC hypersensitivity or HLA-B*5701 in South African children, available data suggest that black children are at lower risk than Caucasian children, with no data on children of mixed race. Although screening for HLA-B*5701 is recommended and will prevent cases, research is needed to assess its cost effectiveness in the South African public health setting.

Acknowledgement

We thank the staff from PathCare for their assistance and Drs B Leibbrandt and Clair Edson for providing patient details. We also thank Dr Leon Levin and Dr Tammy Meyers for their editorial contribution.

REFERENCES

1. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without neflavin in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359: 733-740.
15. Abacavir warning: certain respiratory symptoms can indicate hypersensitivity reaction. AIDS Treat News 2000; No. 237.
30. Abacavir warning: certain respiratory symptoms can indicate hypersensitivity reaction. AIDS Treat News 2000; No. 237.